Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Enhanced Adipose Mesenchymal Stem Cells Proliferation by Carboxymethyl-Chitosan Functionalized Polycaprolactone Nanofiber.

Shapourzadeh A., Atyabi SM., Irani S., Bakhshi H.

Animal Study on Face & Skin, published in Iran Biomed J (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Iran Biomed J (2020)
Country
Iran
Reported sample size
—
Source database
PubMed
PMID
32306721
PMCID
PMC7275816
DOI
10.29252/ibj.24.4.236
Citations
3

Abstract (original English)

Through combining two synthetic and natural polymers, scaffolds can be developed for tissue engineering and regenerative medicine purposes. In this work, carboxymethyl chitosan (CMC; 20%) was grafted to Polycaprolactone (PCL) nanofibers using the cold atmospheric plasma of helium. The PCL scaffolds were exposed to CAP, and functional groups were developed on the PCL surface. The results of Fourier Transform Infrared Spectroscopy confirmed CMC (20%) graft on PCL scaffold. The Thiazolyl blue tetrazolium bromide assay showed a significant enhancement (p < 0.05) in the cell affinity and proliferation of adipose-derived stem cells (ADSCs) to CMC20%-graft-PCL scaffolds. After 14 days, bone differentiation was affirmed through alizarin red and calcium depositions. Based on the results, the CMC20%-graft-PCL can support the proliferation of ADSCs and induce the differentiation into bone with longer culture time.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCalciumCell AdhesionCell ProliferationCell SurvivalChitosanHumansMesenchymal Stem CellsNanofibersPlasma Gases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research